翻訳と辞書 Words near each other ・ "O" Is for Outlaw ・ "O"-Jung.Ban.Hap. ・ "Ode-to-Napoleon" hexachord ・ "Oh Yeah!" Live ・ "Our Contemporary" regional art exhibition (Leningrad, 1975) ・ "P" Is for Peril ・ "Pimpernel" Smith ・ "Polish death camp" controversy ・ "Pro knigi" ("About books") ・ "Prosopa" Greek Television Awards ・ "Pussy Cats" Starring the Walkmen ・ "Q" Is for Quarry ・ "R" Is for Ricochet ・ "R" The King (2016 film) ・ "Rags" Ragland ・ ! (album) ・ ! (disambiguation) ・ !! ・ !!! ・ !!! (album) ・ !!Destroy-Oh-Boy!! ・ !Action Pact! ・ !Arriba! La Pachanga ・ !Hero ・ !Hero (album) ・ !Kung language ・ !Oka Tokat ・ !PAUS3 ・ !T.O.O.H.! ・ !Women Art Revolution Dictionary Lists mini英和辞書 mini和英辞書 Webster 1913 Latin-English FOLDOC Wikipedia English ウィキペディア

翻訳と辞書　辞書検索 [ 開発暫定版 ] スポンサード リンク abiraterone ： ウィキペディア英語版 Abiraterone acetate Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, and is marketed under the trade name Zytiga. In addition, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro. In April 2011, abiraterone acetate was approved by the U.S. Food and Drug Administration (FDA).〔(J&J Expands Options For Prostate Cancer ), ''Investor's Business Daily'', 24 September 2010〕 The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the trial was stopped early because of the successful outcome. ==Medical uses== Abiraterone acetate is indicated for use in combination with prednisone as a treatment for metastatic castration-resistant prostate cancer. It has received FDA (28 April 2011), EMA (23 September 2011), MHRA (5 September 2011) and TGA (1 March 2012) approval for this indication.〔〔〔〔 In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with prednisone/prednisolone (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone acetate has commenced).〔(【引用サイトリンク】work=Pharmaceutical Benefits Scheme )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Abiraterone acetate」の詳細全文を読む スポンサード リンク 翻訳と辞書 : 翻訳のためのインターネットリソース Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.